ReviewRegenerative biomaterials2026
Engineered nanomedicine triggering ROS storms for enhanced cancer therapeutics.
Review in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS) play a significant role in regulating various signaling pathways and biochemical reactions within cells during their proliferation and differentiation. Nonetheless, when excessive ROS are accumulated within cells, they will cause severe damage to cellular components like DNA, proteins and lipids. With advances in nanotechnology, 'ROS storm' has become a promising multifaceted therapeutic strategy for tumor treatment, whose mechanism mainly lies in inducing a massive ROS surge within tumors via synthesis optimization, the modulation of tumor adaptive responses and overcoming inherent constraints of individual ROS, so as to exceed the fatal threshold, thereby leading to severe oxidative damage. Therefore, in this review, we would like to focus on the specific strategies of engineered nanomaterials for triggering ROS storms in tumor tissues and the resultant effects, which have been primarily described in terms of augmenting substrate supply, inhibiting antioxidant systems, enhancing catalytic efficiency, enriching the diversity of reactive species and intensifying targeting accumulation, respectively. Moreover, the strong potential of combining this strategy with therapies such as immunotherapy has been demonstrated in various studies and constitutes a key focus of our discussion. At the end of the review, the future outlook and the remaining challenges when it comes to clinical application have also been discussed. This review is aimed at providing an overview of previous anti-cancer studies based on ROS storm, and shedding new light on this innovative strategy with fresh perspectives, thereby facilitating advances in cancer nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.